<unk>  (Arachis hypogaea)<unk><unk> , sold under the brand name Palforzia, is an oral medication for the treatment of allergic reactions, including anaphylaxis, in children typically aged between four and 17 years of age who have confirmed cases of<unk>  allergy. It is taken by mouth.<unk>  (Arachis hypogaea)<unk><unk>  is a<unk>  that is manufactured from<unk> s and packaged in pull-apart color-coded capsules for dose escalation and up-dosing, and in a sachet for maintenance treatment. The<unk>  is emptied from the capsules or sachet and mixed with a small amount of semisolid food, such as applesauce, yogurt, or pudding for consumption. The most common side effects of<unk>  (Arachis hypogaea)<unk><unk>  are abdominal pain, vomiting, nausea, tingling in the mouth, itching (including in the mouth and ears), cough, runny nose, throat irritation and tightness, hives, wheezing and shortness of breath and anaphylaxis.<unk>  (Arachis hypogaea)<unk><unk>  should not be administered to those with uncontrolled asthma. To mitigate the risk of anaphylaxis associated with<unk>  (Arachis hypogaea)<unk><unk> , the U.S. Food and Drug Administration (FDA) requires a Risk Evaluation and Mitigation Strategy (REMS).<unk>  (Arachis hypogaea)<unk><unk>  is only available through specially certified healthcare providers, health care settings, and pharmacies to those who are enrolled in the REMS program. The FDA is requiring that healthcare providers who prescribe<unk>  (Arachis hypogaea)<unk><unk>  - and healthcare settings that dispense and administer<unk>  (Arachis hypogaea)<unk><unk>  - are educated on the risk of anaphylaxis associated with its use. In addition, the Initial Dose Escalation phase and first dose of each Up-Dosing level must only be administered to patients in a certified healthcare setting equipped to monitor patients and to identify and manage anaphylaxis. Patients or their parents or caregivers must also be counseled on the need for the patients to have injectable epinephrine available for immediate use at all times, the need for continued dietary<unk>  avoidance, and how to recognize the signs and symptoms of anaphylaxis. In January 2020, the FDA approved the drug to Aimmune Therapeutics for mitigating "allergic reactions, including anaphylaxis, that may occur with accidental exposure to<unk> s." It is the first drug approved for<unk>  allergies. It will not make allergic people to be able to eat normal amounts of<unk> s, but will prevent allergies due to accidental eating.
Peanut allergen powder
Saw palmetto extract
Dissolvable tobacco
Toxic cough syrup
Diquafosol
Herbal smokeless tobacco
Herbal cigarette
Caphosol